The between-group difference in restricted mean arthritis-free survival time seen at 2 years persisted at 4 years.

Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please ...

"Real-world" data from the Swedish Rheumatology Quality register show that patients with rheumatoid arthritis (RA) for whom abatacept (Orencia, Bristol-Myers Squibb) is the first biologic ...

In this double-blind phase 2 study, patients with undifferentiated arthritis (defined by ≥ 2 swollen joints but not fulfilling ACR RA criteria) of < 18 months' duration and anti-cyclic citrullinated ...

Patients with rheumatoid arthritis (RA) who also had chronic obstructive pulmonary disease (COPD) had no increased risk of serious respiratory complications when treated with abatacept (Orencia), a ...

Please provide your email address to receive an email when new articles are posted on . A recent study on the benefits of abatacept for patients with moderate-to-severe Crohn’s disease or ulcerative ...

High-risk patients in the the study were seropositive, had arthralgia, and showed signs of inflammation on MRI, according to the presentation at the American College of Rheumatology (ACR) virtual ...

Philip Day loved playing soccer so much that the 35-year-old software engineer founded a website -- FootballMatcher.com -- to help people connect for pickup games. The fun went on pause when Day ...

Bristol-Myers Squibb Company (NYSE: BMY) today announced the results of year two data from AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis (RA) Subjects With ...

Efficacy and Safety Data Further Supporting Use of ORENCIA in New-to-Biologic Patients with Moderate to Severe Rheumatoid Arthritis Added to Product Labeling NEW YORK--(BUSINESS WIRE)--Bristol-Myers ...

One-year treatment with abatacept delays progression to rheumatoid arthritis for up to 4 years among at-risk patients.